Hengrui’s Trastuzumab Rezetecan and Adebrelimab Granted Breakthrough Therapy Designation by China’s NMPA
China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd. (HKG: 1276, SHA: 600276) announced on August 11, 2025,...
Drug
Novartis Begins Shipping Next-Gen Anti-VEGF Drug Beovu for Diabetic Macular Edema
Swiss pharmaceutical giant Novartis (NYSE: NVS) announced on August 11, 2025, the initiation of commercial...
Arvinas and Pfizer’s Vepdegestrant NDA Accepted by FDA for ER+/HER2- Breast Cancer
Arvinas, Inc. (NASDAQ: ARVN) and its partner Pfizer (NYSE: PFE) announced on August 8, 2025,...
Mabwell Initiates U.S. Clinical Study of 9MW2821 for Triple-Negative Breast Cancer
China-based Mabwell (Shanghai) Bioscience Co., Ltd (SHA: 688062) announced the first patient dosing in the...
Akeso Announces Enrollment of First Patient in Ivonescimab Phase 3 Trial for Small Cell Lung Carcinoma
China-based Akeso Biopharma (HKG: 9926) announced that the first patient has been enrolled in the phase...
Junshi Biosciences’ Toripalimab Receives NMPA Acceptance for HER2-expressing UC Treatment
China’s Shanghai Junshi Biosciences Co., Ltd (HKG: 1877, SHA: 688180) announced that it has received...
Shandong Boan’s Boyouping Receives NMPA Approval for Type 2 Diabetes Treatment
Shandong Boan Biotechnology Co., Ltd (HKG: 6955) announced on August 8, 2025, that its self-developed...
Boehringer Ingelheim’s HERNEXEOS Receives FDA Accelerated Approval for NSCLC Treatment
German pharmaceutical giant Boehringer Ingelheim (BI) announced that its HERNEXEOS (zongertinib tablets) has received accelerated...
Johnson & Johnson’s Rybrevant Approved by China’s NMPA for EGFR-Mutant NSCLC Treatment
US giant Johnson & Johnson (J&J, NYSE: JNJ) announced that China’s National Medical Products Administration...
Bio-Thera Solutions Receives NMPA Approval for Combination Therapy Clinical Trial in Advanced Solid Tumors
China-based Bio-Thera Solutions, Ltd. (SHA: 688177) announced that it has received a Drug Clinical Trial...
Jingxin Pharma Signs Patent License for Cariprazine Hydrochloride With Gedeon Richter
China-based Jingxin Pharmaceutical Co., Ltd. (SHE: 002020) announced that it has signed a Patent License...
Teleflex’s Rüsch EZ-Blocker Gets NMPA Approval for China Market
US-based Teleflex Incorporated (NYSE: TFX) announced that its Rüsch EZ-Blocker single-use bronchial blocker has received...
Haisco’s HSK47388 Receives NMPA Clinical Trial Approval for Autoimmune Diseases
China-based Haisco Pharmaceutical Group Co., Ltd (SHE: 002653) announced that it has received clinical trial...
Henlius’ HLX43 Approved by FDA for Phase 1 Trial in Thymic Carcinoma Treatment
China’s Shanghai Henlius Biotech Inc. (HKG: 2696) announced that the U.S. Food and Drug Administration...
Sino Biopharmaceutical’s LM-24C5 Receives NMPA Approval for Phase 2 Clinical Trials in CEACAM5-Positive Solid Tumors
Sino Biopharmaceutical Limited (HKG: 1177) announced that its independently developed LM-24C5 has received clinical trial...
Eli Lilly Reports Strong Q2 Growth but Shares Dip on Orforglipron Data
US pharmaceutical giant Eli Lilly & Co. (NYSE: LLY) reported another strong quarterly performance with...
NHSA Updates Volume-Based Procurement Policy for Medical Institutions in 11th VBP Tender
The National Healthcare Security Administration (NHSA) has released Q&As on the medical institutions’ volumes filing...
Neowise Biotechnology’s NW-101C Receives NMPA Clinical Trial Approval for PRAME-Targeted TCR-T Therapy
China-based Neowise Biotechnology (Suzhou) Co., Ltd. announced that its self-developed PRAME-targeting autologous TCR-T cell therapy...
Dizal Pharma’s DZD8586 Granted FDA Fast Track Designation for CLL/SLL Treatment
Dizal (Jiangsu) Pharmaceutical Co., Ltd (SHA: 688192) announced that its investigational product DZD8586 has been...
AstraZeneca’s Fasenra Approved for Pediatric Severe Eosinophilic Asthma in China
UK-based pharmaceutical giant AstraZeneca (AZ; NASDAQ: AZN) announced the official approval of a new indication...